| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0006-2952(97)00657-6 |
| P698 | PubMed publication ID | 10076535 |
| P2093 | author name string | X M Liu | |
| D R Budman | |||
| L G Wang | |||
| W Kreis | |||
| P2860 | cites work | The steroid and thyroid hormone receptor superfamily | Q27861095 |
| Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation | Q28284288 | ||
| Clinical pharmacokinetics of estramustine phosphate | Q40179005 | ||
| Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines | Q41130409 | ||
| Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer | Q41344070 | ||
| Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors | Q41510505 | ||
| The promoter of the prostate-specific antigen gene contains a functional androgen responsive element | Q41655072 | ||
| A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens | Q44507804 | ||
| Synergism between androgens and protein kinase-C on androgen-regulated gene expression | Q44950083 | ||
| The hydrolysis of estramustine phosphate; in vitro studies | Q59485409 | ||
| Growth inhibiting effect of estramustine on two prostatic carcinoma cell lines, LNCaP and LNCaP-r | Q67986180 | ||
| Regulation of growth and epidermal growth factor receptor levels of LNCaP prostate tumor cells by different steroids | Q68100059 | ||
| Distribution and metabolism of estramustine in HeLa cells and the human prostatic tumour cell line 1013L | Q68462879 | ||
| Effect of estramustine phosphate on the assembly of trypsin-treated microtubules and microtubules reconstituted from purified tubulin with either tau, MAP2, or the tubulin-binding fragment of MAP2 | Q70358146 | ||
| Induction of differentiation and down-regulation of c-myb gene expression in ML-1 human myeloblastic leukemia cells by the clinically effective anti-leukemia agent meisoindigo | Q71077815 | ||
| Estramustine-induced mitotic arrest in two human prostatic carcinoma cell lines DU 145 and PC-3 | Q71264628 | ||
| Hydroxyflutamide may not always be a pure antiandrogen | Q73273929 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1427-33 | |
| P577 | publication date | 1998-05-01 | |
| P1433 | published in | Biochemical Pharmacology | Q864229 |
| P1476 | title | Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor | |
| P478 | volume | 55 |
| Q43740772 | Changes in prostate-specific antigen (PSA) level correlate with growth inhibition of prostate cancer cells treated in vitro with a novel anticancer drug, irofulven |
| Q40146115 | Coprinus comatus and Ganoderma lucidum interfere with androgen receptor function in LNCaP prostate cancer cells |
| Q40821551 | Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma |
| Q34707836 | Recent advances in chemotherapy for advanced prostate cancer |
| Q78251649 | Synergistic effect of estramustine and [3'-keto-Bmtl]-[Val2]-cyclosporine (PSC 833) on the inhibition of androgen receptor phosphorylation in LNCaP cells |
| Q30486738 | The Concise Guide to PHARMACOLOGY 2013/14: nuclear hormone receptors |
| Q34318315 | The androgen receptor acetylation site regulates cAMP and AKT but not ERK-induced activity. |
| Q35193278 | The androgen receptor: structure, mutations, and antiandrogens |
Search more.